Keytruda Clears Low Hurdle In Stage III Melanoma
Merck & Co's Keytruda hits endpoint in KEYNOTE-054 as a monotherapy for high-risk patients but the low bar set by the placebo comparator means that rival Opdivo should keep its edge.
Merck & Co's Keytruda hits endpoint in KEYNOTE-054 as a monotherapy for high-risk patients but the low bar set by the placebo comparator means that rival Opdivo should keep its edge.